Filing Details
- Accession Number:
- 0001127602-12-009002
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2012-03-01 18:13:04
- Reporting Period:
- 2012-02-28
- Filing Date:
- 2012-03-01
- Accepted Time:
- 2012-03-01 18:13:04
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1097264 | Allos Therapeutics Inc | ALTH | Pharmaceutical Preparations (2834) | 541655029 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1489966 | Q Charles Morris | 11080 Circlepoint Road Suite 200 Westminster CO 80020 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2012-02-28 | 241,848 | $0.00 | 683,448 | No | 4 | A | Direct | |
Common Stock | Disposition | 2012-02-29 | 10,155 | $1.52 | 673,293 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | S | Direct |
Footnotes
- Represents shares of common stock issued as restricted stock units ("RSUs") awarded under the Company's 2008 Equity Incentive Plan (the "Plan"). The RSUs shall vest in a series of eight (8) successive equal semi-annual installments over the four (4)-year period measured from March 18, 2012 (the "Vesting Commencement Date"), subject to Participant's Continuous Service through each such date.
- These shares are being sold pursuant to a 10b5-1 plan for Charles Q. Morris in order to cover the withholding tax and other costs associated with such sale (i.e., wire fees, commission or interest) in connection with the vesting of restricted stock units on February 28, 2012.
- The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $1.52 to $1.54. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.